Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

When Size Matters: Advanced Treatment of Acute Pulmonary Embolism Caused by a Large Snake-Like Thrombus.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

Same author

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Med (New York, N.Y.)·2026

Same author

Clinical, Metabolic, and Virological Insights into Hepatitis C Virus-Infected Patients through the Combinatorial Metabolic Dysfunction-associated Steatotic Liver Disease Framework: Evidence from an Italian Cohort.

Journal of gastrointestinal and liver diseases : JGLD·2026

Same author

Safety of Invasive Procedures During Adult Extracorporeal Membrane Oxygenation: A Systematic Review.

Journal of clinical medicine·2026

Same author

Orthohantavirus Infection Mimicking Acute Viral Hepatitis: An Underrecognized Clinical Presentation.

Pathogens (Basel, Switzerland)·2026

Same author

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Cancer·2026

Search research articles

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities.

Chiara Catania^1,2, Priscilla Cascetta¹, Alessandro Russo³

¹Division of Oncology, Humanitas Gavazzeni, 24125 Bergamo, Italy.

Current Oncology (Toronto, Ont.)

|October 28, 2025

Summary

This summary is machine-generated.

Small Cell Lung Cancer (SCLC) is aggressive, but understanding exceptional responders is key. Integrating biomarkers and novel therapies offers hope for improved precision oncology and patient outcomes.

Keywords:

immunotherapy molecular subtype precision oncology small cell lung cancer

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Area of Science:

Oncology
Molecular Biology
Immunotherapy

Background:

Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor with a poor prognosis.
Despite initial treatment responses, acquired resistance leads to inevitable relapse in most patients.
Current clinical classification lacks the granularity to support precision medicine strategies.

Purpose of the Study:

To explore the molecular and immunological profiles of exceptional responders in SCLC.
To identify potential biomarkers for predicting treatment response and guiding precision oncology.
To discuss the role of novel therapeutic agents and multi-dimensional profiling in advancing SCLC treatment.

Main Methods:

Review of molecular studies identifying SCLC subtypes (ASCL1, NEUROD1, POU2F3, YAP1).
Analysis of clinical trial data (IMpower133, CASPIAN, ADRIATIC) for immunotherapy outcomes.
Discussion of emerging biomarkers (PD-L1, TMB, DLL3, CD3, B7-H3) and novel agents (tarlatamab, ifinatamab deruxtecan).

Main Results:

SCLC subtypes exhibit distinct biological traits and vulnerabilities.
Immunotherapy has modestly improved survival but long-term responders remain a small subset (~12%).
Novel agents show promise, but predictive markers are still needed.

Conclusions:

Understanding exceptional responders is critical for advancing SCLC treatment.
Comprehensive biomarker integration (tissue, blood, immune profiling) is essential.
A multi-dimensional approach will improve patient selection for emerging precision therapies.